VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017

May 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-05-15

Reporting Person: SMITH IAN F (EVP, CFO & COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-15	Common Stock	S	294	$114.92	Disposed	126238	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5306	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $114.92 (range $114.37 to $115.21).

F3: Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.